{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:50:36Z","timestamp":1777477836276,"version":"3.51.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi and Regeneron Pharmaceuticals Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sleep disturbance is a prominent symptom of atopic dermatitis (AD) and can result in insomnia, daytime fatigue, drowsiness, reduced productivity and impaired quality of life (QoL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The Dupilumab Effect on Sleep in AD Patients (DUPISTAD) phase IV randomized double-blinded placebo-controlled study evaluated the impact of dupilumab treatment on sleep and other patient- and physician-reported outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults with moderate-to-severe AD were randomized 2 : 1 to dupilumab 300\u2005mg once every 2 weeks (q2w) or placebo for 12\u00a0weeks; concomitant topical corticosteroids were permitted. Patients subsequently entered an open-label phase and received dupilumab 300\u2005mg q2w for a further 12 weeks. The primary endpoint was the percentage change in sleep quality from baseline to week 12, assessed using a novel numeric rating scale (NRS). Secondary and exploratory endpoints included percentage change in peak pruritus NRS (PP NRS), change in SCORing Atopic Dermatitis (SCORAD), SCORAD sleep visual analogue scale (VAS), Eczema Area and Severity Index, Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score and the Epworth Sleepiness Scale. Sleep diary and wrist actigraphy measurements were recorded throughout the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 127 patients received dupilumab and 61 patients received placebo. Demographic and baseline disease characteristics were balanced between groups. Sleep quality NRS significantly improved in patients treated with dupilumab by week 12 vs. placebo [least squares mean of the difference (LSMD) \u221215.5%, P &amp;lt; 0.001]. PP NRS (LSMD \u221227.9%, P &amp;lt; 0.001), SCORAD (LSMD \u221215.1, P &amp;lt; 0.001), SCORAD sleep VAS (LSMD \u22122.1, P &amp;lt; 0.001) and PROMIS T-score (LSMD \u22123.6, P &amp;lt; 0.001) were also significantly improved at week 12 with dupilumab vs. placebo. The overall percentage of patients reporting treatment-emergent adverse events was lower in the dupilumab group (56.7%) than in the placebo group (67.2%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dupilumab significantly improved sleep quality and perception of sleep continuity, itch, metrics of AD severity and QoL in adults with moderate-to-severe AD, with an acceptable safety profile compared with placebo.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad284","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T12:55:40Z","timestamp":1691585740000},"page":"685-694","source":"Crossref","is-referenced-by-count":22,"title":["Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study"],"prefix":"10.1093","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F","family":"Merola","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital , Boston, MA , USA"},{"name":"Harvard Medical School , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8436-0008","authenticated-orcid":false,"given":"Albert S","family":"Chiou","sequence":"additional","affiliation":[{"name":"Department of Dermatology,\u00a0Stanford University, Palo Alto, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-5115","authenticated-orcid":false,"given":"Emmanuel","family":"During","sequence":"additional","affiliation":[{"name":"Department of Neurology & Neurological Sciences, Stanford University, Palo Alto, CA, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Division of Sleep Medicine, Stanford University , Palo Alto, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital , Rozzano, Milan , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Foley","sequence":"additional","affiliation":[{"name":"Skin Health Institute , Carlton, VIC , Australia"},{"name":"Department of Dermatology, St Vincent\u2019s Hospital Melbourne , Fitzroy, VIC , Australia"},{"name":"Department of Medicine, The University of Melbourne , Melbourne, VIC , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"Amani","family":"Alfalasi","sequence":"additional","affiliation":[{"name":"Al Safa Dermatology Clinic , Dubai , United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaila","family":"Gogate","sequence":"additional","affiliation":[{"name":"Colorado Allergy & Asthma Centers , Denver, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Frankfurt am Main , Frankfurt am Main , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2168-3798","authenticated-orcid":false,"given":"Roni","family":"Dodiuk-Gad","sequence":"additional","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion Institute of Technology , Haifa , Israel"},{"name":"Division of Dermatology, Department of Medicine, University of Toronto , Toronto, ON , Canada"},{"name":"Dermatology Department, Emek Medical Center , Afula , Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-9407","authenticated-orcid":false,"given":"Dagmar","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsspital Bern , Bern , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6245-7442","authenticated-orcid":false,"given":"Marie","family":"Tauber","sequence":"additional","affiliation":[{"name":"Department of Allergology and Clinical Immunology, CIRI Inserm U1111, Lyon Sud Hospital , Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2550-9586","authenticated-orcid":false,"given":"Richard","family":"Weller","sequence":"additional","affiliation":[{"name":"Centre for Inflammation Research, University of Edinburgh , Edinburgh , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6843-5877","authenticated-orcid":false,"given":"Jose-Juan","family":"Pereyra-Rodriguez","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Hospital Universitario Virgen del Rocio , Sevilla , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7712-6862","authenticated-orcid":false,"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc. , Tarrytown, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangming","family":"Wu","sequence":"additional","affiliation":[{"name":"Sanofi , Bridgewater, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer E","family":"Ozturk","sequence":"additional","affiliation":[{"name":"Sanofi , Cambridge, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"2023112113513469500_ljad284-B1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"2023112113513469500_ljad284-B2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.mcna.2019.08.009","article-title":"Atopic dermatitis in adults","volume":"104","author":"Silverberg","year":"2020","journal-title":"Med Clin North Am"},{"key":"2023112113513469500_ljad284-B3","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"key":"2023112113513469500_ljad284-B4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2023112113513469500_ljad284-B5","doi-asserted-by":"crossref","first-page":"644760","DOI":"10.3389\/fmed.2021.644760","article-title":"Itch in atopic dermatitis\u00a0\u2013 what is new?","volume":"8","author":"Legat","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2023112113513469500_ljad284-B6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2023112113513469500_ljad284-B7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/jid.2014.325","article-title":"Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study","volume":"135","author":"Silverberg","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2023112113513469500_ljad284-B8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.det.2017.02.004","article-title":"Patient burden of atopic dermatitis","volume":"35","author":"Sibbald","year":"2017","journal-title":"Dermatol Clin"},{"key":"2023112113513469500_ljad284-B9","first-page":"267","article-title":"Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4\u20135\u2005hours per night","volume":"20","author":"Dinges","year":"1997","journal-title":"Sleep"},{"key":"2023112113513469500_ljad284-B10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s13555-017-0192-3","article-title":"Frequency and management of sleep disturbance in adults with atopic dermatitis: a systematic review","volume":"7","author":"Jeon","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023112113513469500_ljad284-B11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jdv.15634","article-title":"Atopic eczema: burden of disease and individual suffering\u00a0\u2013 results from a large EU study in adults","volume":"33","author":"Ring","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023112113513469500_ljad284-B12","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.jid.2020.03.961","article-title":"Development and initial psychometric properties of two itch-\u00adrelated measures: scratch intensity and impact, sleep-related itch and scratch","volume":"140","author":"Heckman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2023112113513469500_ljad284-B13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2340\/00015555-2480","article-title":"What factors are important to patients when assessing treatment response: an international cross-sectional survey","volume":"97","author":"von Kobyletzki","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2023112113513469500_ljad284-B14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/DER.0000000000000161","article-title":"Burden of sleep and fatigue in US adults with atopic dermatitis","volume":"27","author":"Yu","year":"2016","journal-title":"Dermatitis"},{"key":"2023112113513469500_ljad284-B15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/jdv.15973","article-title":"Neuroimmune interactions in chronic itch of atopic dermatitis","volume":"34","author":"Yosipovitch","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023112113513469500_ljad284-B16","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023112113513469500_ljad284-B17","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023112113513469500_ljad284-B18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"2023112113513469500_ljad284-B19","doi-asserted-by":"crossref","first-page":"e.130\u20133","DOI":"10.1111\/jdv.16865","article-title":"Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials","volume":"35","author":"Beck","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023112113513469500_ljad284-B20","author":"US Food and Drug Administration"},{"key":"2023112113513469500_ljad284-B21","author":"European Medicines Agency"},{"key":"2023112113513469500_ljad284-B22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/bjd.20783","article-title":"Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis","volume":"186","author":"Puelles","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023112113513469500_ljad284-B23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023112113513469500_ljad284-B24","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1398-9995.2011.02577.x","article-title":"Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe","volume":"66","author":"Stalder","year":"2011","journal-title":"Allergy"},{"key":"2023112113513469500_ljad284-B25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"key":"2023112113513469500_ljad284-B26","first-page":"997","article-title":"The Dermatology Life Quality Index 1994\u20132007: a comprehensive review of validation data and clinical results","volume":"159","author":"Basra","year":"2008","journal-title":"Br J Dermatol"},{"key":"2023112113513469500_ljad284-B27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","article-title":"EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference","volume":"67","author":"Schram","year":"2012","journal-title":"Allergy"},{"key":"2023112113513469500_ljad284-B28","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/bjd.15641","article-title":"Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis","volume":"177","author":"Chopra","year":"2017","journal-title":"Br J Dermatol"},{"key":"2023112113513469500_ljad284-B29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"2023112113513469500_ljad284-B30","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"2023112113513469500_ljad284-B31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/npp.2016.148","article-title":"Sleep health: reciprocal regulation of sleep and innate immunity","volume":"42","author":"Irwin","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"2023112113513469500_ljad284-B32","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required\u00a0to\u00a0broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"key":"2023112113513469500_ljad284-B33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2023112113513469500_ljad284-B34","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.19457","article-title":"What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023112113513469500_ljad284-B35","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.anai.2018.07.004","article-title":"Severity strata for\u00a0POEM, PO-SCORAD, and DLQI in US adults with atopic\u00a0\u00addermatitis","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023112113513469500_ljad284-B36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1745691614556680","article-title":"Sleep, cognition, and normal aging: integrating a half century of multidisciplinary research","volume":"10","author":"Scullin","year":"2015","journal-title":"Perspect Psychol Sci"},{"key":"2023112113513469500_ljad284-B37","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1378\/chest.10-1872","article-title":"Wrist actigraphy","volume":"139","author":"Martin","year":"2011","journal-title":"Chest"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad284\/51650264\/ljad284.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/6\/685\/53664548\/ljad284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/6\/685\/53664548\/ljad284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:50:15Z","timestamp":1700585415000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/6\/685\/7240714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,8,10]]},"published-print":{"date-parts":[[2023,11,16]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad284","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,8,10]]}}}